
Back pain is one of the most common complaints I see in my clinic. The vast majority of the time, it turns out to be something manageable — a [↗ disc bulge], [↗ muscle strain], or [↗ sciatica]. We sort it out, the patient gets better, and life goes on.
But every so often — not often, but often enough — I see a patient whose back pain is something more serious. Something that needs to be caught early, investigated properly, and treated urgently.
Spine cancer is rare. But it is also one of the most commonly misdiagnosed conditions in my field, precisely because its earliest symptom — back pain — looks exactly like something much more common. A delayed diagnosis can mean the difference between a full recovery and permanent disability.
That's why I'm writing this. Not to frighten you — but to make sure you know what to look for, when to push for investigation, and what modern treatment looks like if spine cancer is diagnosed. Knowledge, in this case, genuinely saves lives.
The spine is not just a stack of bones. It houses the spinal cord — the information superhighway between your brain and the rest of your body — along with nerve roots, blood vessels, protective membranes, and soft tissues. Spine cancer can arise from any of these structures, or it can arrive from somewhere else entirely.
The most important distinction in spine oncology is where the cancer originated:
We also classify tumours by their anatomical relationship to the dura — the tough outer membrane that wraps around the spinal cord. This directly shapes the surgical plan and the expected outcome:
Worth knowing: The spine is the most common site of bone metastasis after the lungs and liver. Any patient with a known cancer history who develops new persistent back pain must be evaluated for spinal involvement — not managed with pain medication alone.
Primary spinal tumours are classified by their cell of origin. Here are the most clinically important types:
The most common primary spinal cord tumour in adults. Ependymomas arise from the ependymal cells lining the central canal of the cord, and most often appear in the lower cord and filum terminale.
The encouraging news: they tend to have well-defined borders, giving the surgeon a realistic chance of complete removal. With a successful total resection, the long-term outcome is often excellent.
Unlike ependymomas, astrocytomas are infiltrative — their edges blend into surrounding cord tissue, making complete resection extremely difficult without causing harm. They are the most common spinal cord tumour in children and typically appear in the thoracic spine in adults.
Meningiomas grow from the meninges — the protective membranes around the spinal cord. They are more common in women and older adults. Most are grade 1 (benign) and, if caught before causing serious cord damage, can be completely removed with an excellent prognosis.
These tumours develop around the nerve roots. Almost always benign, they typically present with radicular pain — a shooting, electric sensation along the nerve's pathway — which can be mistaken for [↗ sciatica] or [↗ disc herniation]. MRI makes the distinction clearly.
A rare, slow-growing malignant tumour arising from remnants of the embryonic notochord. Chordomas most often appear at the base of the skull or the sacrum and have a stubborn tendency to recur. Treatment involves wide surgical resection combined with specialised high-dose radiation.
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma can arise directly in the vertebral bones, most often in younger patients. These require a multimodal approach — surgery, chemotherapy, and radiation — planned together from the outset.
This is what I see far more often in my clinic. A patient — sometimes already undergoing cancer treatment, sometimes with no prior diagnosis — develops new back pain. We scan them, and there it is.
Breast, lung, and prostate cancers together account for more than 80% of metastatic bone disease.
In descending order of frequency, the primary cancers most likely to spread to the spine are:
Heads up: Metastatic spinal disease most commonly affects the thoracic spine (mid-back), followed by the lumbar spine. The thoracic region is particularly high-risk because there is less space around the spinal cord at this level — even a small tumour can cause cord compression.
I want to be very clear about something before we go further. Most back pain is not cancer. The vast majority of patients who come to me have a [↗ disc bulge], a [↗ muscle problem], or wear-and-tear arthritis. Please do not read this section and immediately assume the worst.
But there is a specific pattern of pain — and a set of accompanying symptoms — that is genuinely different. Learning to recognise it could save a life.
The pain from a spinal tumour doesn't behave the way normal [↗ back pain] does. Here is what makes it different:
As a tumour grows and presses on the spinal cord or nerve roots, neurological symptoms emerge. These vary by spinal level:
These symptoms, when combined with back pain, should send you straight to your doctor:
�� This Cannot Wait: If you have a history of cancer — any cancer — and you develop new back pain, please tell your oncologist or GP immediately and ask for an MRI. If you develop progressive limb weakness, difficulty walking, or bowel and bladder changes alongside back or neck pain, go to the emergency department the same day. These are spinal oncological emergencies.
When I suspect a spinal tumour, we don't waste time. An accurate diagnosis needs to be made quickly, because neurological damage from spinal cord compression can become permanent within hours to days.
Before any scan, I do a thorough clinical assessment — the kind that takes time and genuinely matters. I want to understand the full story of the pain: how it started, how it's behaving, and whether there's any history of cancer. I test neurological function — muscle strength, reflexes, and sensation in the limbs — to identify exactly which spinal level is involved.
One telling physical sign: pressing on the spine itself (percussion tenderness). Focal midline bony tenderness that is severe and localised is more typical of vertebral pathology — a tumour or a fracture — than of the muscle-related back pain I encounter every day.
Knowing there's a tumour is not enough. We need to know exactly what type it is, because histology drives every treatment decision — which chemotherapy, what radiation dose, and whether surgery is appropriate.
For most vertebral lesions, we perform a CT-guided percutaneous needle biopsy — a minimally invasive procedure under local anaesthetic and real-time imaging guidance. For complex intramedullary tumours, open surgical biopsy may be required. In patients with a known primary cancer elsewhere and clear imaging features of metastasis, biopsy may sometimes be deferred — but only after multidisciplinary team discussion.
In spine oncology, we use validated scoring tools to ensure every relevant factor is considered before treatment begins:
Spine cancer treatment is not one-size-fits-all. Two patients with spinal metastases may have completely different treatment plans, because the tumour type, extent of disease, the patient's overall health, and the goals of care all differ.
Every spine cancer case at our centre is discussed by a multidisciplinary team — spine surgeon, medical oncologist, radiation oncologist, pathologist, and radiologist — before a treatment plan is finalised. That collaboration matters enormously.
Surgery is not always the first answer in spine cancer, but when indicated, it can be transformative. The objective depends on the clinical situation:
Traditional external beam radiation delivered in multiple sessions — typically 5 to 30 fractions. Reliable, widely available, and effective for pain control in radiosensitive tumour types like breast cancer, lymphoma, and myeloma.
SBRT is the game-changer. It delivers ablative doses of precisely targeted radiation in just 1–5 sessions, guided by real-time imaging to within millimetres of the target. Published data shows 1-year local control rates exceeding 80% for spinal SBRT, with pain improvement in 65–81% of patients.
For tumour types historically regarded as radioresistant — renal cell carcinoma, melanoma, sarcoma — SBRT is increasingly the treatment of choice. It is also used postoperatively after separation surgery, and is now considered a standard of care for oligometastatic spinal disease.
For patients whose cancer carries a specific molecular driver, we now have drugs that target that driver with remarkable precision:
These agents have genuinely transformed the prognosis for selected metastatic patients. People who previously had a short life expectancy are now living years with well-controlled disease — which also means more patients are living with spinal metastases, and why durable local control with SBRT matters more than ever.
When a patient arrives with acute spinal cord compression, the first thing we do — even before surgery is arranged — is start high-dose dexamethasone. This steroid reduces swelling and inflammation around the compressed cord within hours. It is not a cure, but it can prevent neurological deterioration from worsening while definitive treatment is prepared. In spinal cord compression, every hour counts.
For some patients with widespread metastatic disease, cure is not the goal. And there is nothing wrong with saying that clearly. In those situations, our aim shifts — we focus on managing pain, preserving function, and helping patients maintain their independence and quality of life for as long as possible.
Palliative radiotherapy provides effective pain relief for the majority of patients with painful bone metastases. [↗ Spinal rehabilitation], pain management programmes, and psychological support are as integral to comprehensive care as any operation or drug. We also discuss cancer survivorship programmes proactively — because people living with spinal metastases deserve a care team that plans ahead with them.
Prognosis in spine cancer is genuinely variable, and I'm cautious about giving patients numbers without context. Here are the principles:
Meningiomas and schwannomas carry an excellent prognosis when completely surgically removed — many patients are effectively cured. Ependymomas, when fully resected before significant cord damage, also have a favourable long-term outlook.
High-grade astrocytomas carry a more guarded prognosis given their infiltrative nature and difficulty of complete resection. Chordomas, while slow-growing, require aggressive treatment due to their high recurrence rate. Treatment continues to improve, however, and outcomes today are meaningfully better than they were a decade ago.
Prognosis depends far more on the biology of the primary cancer and the extent of systemic disease than on the spinal involvement alone. Modern systemic therapies have dramatically improved survival for breast, prostate, lung, and kidney cancers — which is why we are seeing more patients living well with metastatic spinal disease than ever before.
The single most important factor across all types is how quickly the diagnosis is made. Neurological deficits present for less than 24–48 hours are often reversible with prompt treatment. Deficits present for weeks may be permanent. This is why back pain that isn't improving the way it should always deserves a proper look.
Clinical principle: Any degree of neurological deficit in the setting of a suspected spinal tumour requires urgent evaluation and treatment. Delays of even 24–48 hours can result in permanent disability that could have been prevented.
Spinal tumours are frequently misattributed to more common conditions because the symptoms genuinely overlap. Here is how I think about the key distinctions:
[↗ Disc bulge] pain is mechanical — worse with movement, sitting, or bending; better with rest. Tumour pain is the opposite: progressive, worse at night, unresponsive to conservative treatment. MRI clearly distinguishes the two, and any 'disc pain' that isn't improving as expected warrants re-evaluation.
Tumour-related nerve pain can look exactly like [↗ sciatica]. The difference lies in accompanying features: progressive weakness, systemic symptoms, a cancer history, or bilateral leg involvement. Any atypical or non-resolving sciatica needs MRI.
Both [↗ spinal infection (spondylodiscitis)] and tumour cause severe, progressive back pain — sometimes with fever. The key MRI differentiator: infections involve the intervertebral disc space; tumours almost always spare the disc. That single sign can make the distinction.
Both can cause sudden vertebral collapse. MRI signal characteristics, patient age, cancer history, and sometimes biopsy help differentiate them. Treating an undiagnosed [↗ pathological fracture] as simple osteoporosis is a mistake with serious consequences.
Most back pain does not need a spine specialist urgently. But the following situations do:
Have a spine or nerve concern? Connect
with Dr. Anup P Nair for clear and personalized guidance.